Compass Therapeutics (CMPX) Free Cash Flow (2018 - 2026)
Compass Therapeutics (CMPX) posted Free Cash Flow of -$17.4 million for Q1 2026, down 30.91% sequentially from -$13.3 million in Q4 2025, and down 31.19% YoY from -$25.2 million in Q1 2025.
Compass Therapeutics (CMPX) Free Cash Flow (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Free Cash Flow for 9 years, with the latest figure at -$17.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 31.19% year-over-year to -$17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.3 million (down 20.47% YoY) and the FY2025 annual result came in at -$49.2 million, down 9.51% from the prior year.
- Free Cash Flow fell to -$17.4 million in Q1 2026 per CMPX's latest filing, from -$13.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$4.5 million in Q2 2022 and troughed at -$17.4 million in Q1 2026.
- A 5-year average of -$11.0 million and a median of -$11.0 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 163.36% in 2022, then jumped 46.19% in 2023.
- Over 5 years, Free Cash Flow stood at -$10.7 million in 2022, then slipped by 15.6% to -$12.4 million in 2023, then advanced by 25.89% to -$9.2 million in 2024, then slumped by 44.66% to -$13.3 million in 2025, then slumped by 30.91% to -$17.4 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$17.4 million, -$13.3 million, and -$10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | -14.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.91 Mn |
| Jun 30, 2026 | -14.91 Mn |
| Mar 31, 2026 | -17.35 Mn |
| Mar 31, 2026 | -17.35 Mn |
| Dec 31, 2025 | -13.25 Mn |
| Dec 31, 2025 | -13.25 Mn |
| Sep 30, 2025 | -10.86 Mn |
| Sep 30, 2025 | -10.86 Mn |
| Jun 30, 2025 | -11.83 Mn |
| Jun 30, 2025 | -11.83 Mn |
| Mar 31, 2025 | -13.23 Mn |
| Mar 31, 2025 | -13.23 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Sep 30, 2024 | -11.10 Mn |
| Sep 30, 2024 | -11.10 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Mar 31, 2024 | -13.89 Mn |
| Mar 31, 2024 | -13.89 Mn |